Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17254311 | FIBROUS WOUND DRESSING COMPRISING AN ANTISEPTIC | December 2020 | August 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17085302 | MANUFACTURING DEVICE FOR GELATIN CAPSULE | October 2020 | August 2023 | Abandon | 33 | 1 | 1 | No | No |
| 16767005 | WOUND-TREATING ABSORBENT | May 2020 | August 2023 | Abandon | 39 | 2 | 0 | No | No |
| 16874601 | TREATMENT OF CANCER | May 2020 | March 2022 | Abandon | 22 | 1 | 0 | No | No |
| 16762384 | BIOMIMETIC PRO-REGENERATIVE SCAFFOLDS AND METHODS OF USE THEREOF | May 2020 | August 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16796409 | OSMOTIC DRUG DELIVERY SYSTEM | February 2020 | November 2022 | Abandon | 33 | 2 | 0 | No | Yes |
| 16496522 | IMPLANTABLE AND REMOVABLE DRUG DELIVERY DEVICE | September 2019 | January 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16463320 | SOLID ORAL COMPOSITION CONTAINING DYES | May 2019 | January 2022 | Abandon | 32 | 1 | 1 | No | No |
| 16343652 | ANTI-MICROBIAL ARTICLES | April 2019 | May 2023 | Abandon | 49 | 1 | 0 | No | No |
| 16267238 | PHARMACEUTICAL COMPOSITIONS | February 2019 | March 2023 | Abandon | 49 | 1 | 1 | No | No |
| 16096955 | AEROSOL GEL COMPOSITION | October 2018 | May 2023 | Abandon | 54 | 3 | 1 | No | No |
| 16159175 | COSMETIC COMPOSITION | October 2018 | May 2023 | Abandon | 55 | 3 | 1 | No | No |
| 16137155 | POLYMER-LIPID HYBRID NANOPARTICLES OF CAPECITABINE UTILIZING MICROMIXING AND CAPECITABINE AMPHIPHILIC PROPERTIES | September 2018 | August 2023 | Abandon | 59 | 4 | 1 | No | No |
| 15945838 | BODY OIL CANDLE | April 2018 | January 2022 | Abandon | 46 | 4 | 0 | No | No |
| 15850308 | BONE FILLER COMPOSITION | December 2017 | August 2022 | Abandon | 55 | 4 | 0 | No | Yes |
| 15845608 | SUGAR-BASED DISPERSION | December 2017 | November 2022 | Abandon | 59 | 2 | 0 | No | Yes |
| 14159119 | LONG TERM DRUG DELIVERY DEVICES WITH POLYURETHANE BASED POLYMERS AND THEIR MANUFACTURE | January 2014 | February 2015 | Abandon | 13 | 1 | 0 | No | No |
| 13945085 | INGESTIBLE CANKER SORE TREATMENT | July 2013 | March 2015 | Abandon | 20 | 1 | 1 | No | No |
| 13822015 | ORAL VETERINARY PREPARATIONS | March 2013 | August 2014 | Abandon | 17 | 1 | 0 | No | No |
| 13755958 | PESTICIDAL COMPOSITIONS CONTAINING ROSEMARY OIL AND WINTERGREEN OIL | January 2013 | June 2014 | Allow | 17 | 1 | 2 | No | No |
| 13745075 | METHOD FOR PREPARING MICROSPHERES AND MICROSPHERES PRODUCED THEREBY | January 2013 | January 2015 | Abandon | 24 | 1 | 0 | No | No |
| 13809265 | TOPICAL USE OF STEVIOL OR DERIVATIVES IN HAIR CARE | January 2013 | March 2015 | Abandon | 27 | 1 | 1 | No | No |
| 13729776 | TOPICAL DRUG DELIVERY SYSTEM WITH DUAL CARRIERS | December 2012 | November 2015 | Abandon | 35 | 2 | 0 | No | Yes |
| 13666773 | COMPOSITIONS AND METHODS FOR REDUCING EDEMA | November 2012 | December 2014 | Abandon | 26 | 1 | 1 | No | No |
| 13648991 | Modified Release Formulations of Anti-Irritability Drugs | October 2012 | March 2015 | Abandon | 30 | 1 | 0 | No | No |
| 13622636 | Even Deposition and Low Rub-Off Compositions | September 2012 | August 2017 | Abandon | 58 | 2 | 0 | No | Yes |
| 13349961 | ONE STEP FIRE ANT CONTROL | January 2012 | November 2014 | Abandon | 34 | 0 | 1 | No | No |
| 13323569 | GOLDEN MEAN HARMONIZED WATER AND AQUEOUS SOLUTIONS | December 2011 | November 2014 | Abandon | 35 | 2 | 0 | No | Yes |
| 13284479 | PEST-CONTROL, COMPOSITIONS, AND METHODS AND PRODUCTS UTILIZING SAME | October 2011 | August 2014 | Abandon | 34 | 1 | 0 | No | No |
| 13001518 | BAIT GRANULE PRODUCTION METHOD | June 2011 | June 2014 | Abandon | 42 | 0 | 1 | No | No |
| 13164584 | Pesticide Treatment Of Soils Or Substrates With Sulphur Compounds | June 2011 | August 2013 | Allow | 26 | 2 | 1 | No | No |
| 13066566 | MYCOATTRACTANTS AND MYCOPESTICIDES | April 2011 | March 2013 | Allow | 23 | 3 | 1 | No | No |
| 13081348 | THIAZOLES AS FUNGICIDES | April 2011 | August 2014 | Abandon | 41 | 0 | 1 | No | No |
| 12863850 | EMULSIFIABLE CONCENTRATE COMPOSITION | July 2010 | June 2014 | Abandon | 47 | 2 | 1 | No | Yes |
| 12803738 | Polymeric endoprostheses with modified erosion rates and methods of manufacture | July 2010 | May 2015 | Abandon | 58 | 4 | 0 | No | Yes |
| 12682133 | USE OF A 1-N-(HALO-3-PYRIDYLMETHYL)-N-METHYLAMINO-1-ALKYLAMINO-2-NITROETHYLENE DERIVATIVE FOR PREPARING A TOPICAL VETERINARY PHARMACEUTICAL COMPOSITION FOR COMBATING EXTERNAL PARASITES | June 2010 | April 2014 | Allow | 48 | 3 | 1 | Yes | No |
| 12776325 | FLUIDIC TISSUE AUGMENTATION COMPOSITIONS AND METHODS | May 2010 | November 2015 | Abandon | 60 | 4 | 1 | No | Yes |
| 12750135 | FOXN1 AND PIGMENTATION | March 2010 | October 2011 | Abandon | 18 | 1 | 1 | No | No |
| 12558813 | FLASHMELT ORAL DOSAGE FORMULATION | September 2009 | September 2011 | Abandon | 24 | 1 | 1 | No | No |
| 12493002 | ORAL SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION OF INDAPAMIDE, PRODUCTION AND USE THEREOF | June 2009 | September 2011 | Abandon | 27 | 1 | 0 | No | No |
| 12520565 | PESTICIDAL COMPOSITION COMPRISING FOSETYL-ALUMINIUM, PROPAMOCARB-HCL AND AN INSECTICIDE SUBSTANCE | June 2009 | April 2016 | Abandon | 60 | 2 | 1 | No | Yes |
| 12471910 | NOVEL PHARMACEUTICAL FORMULATION IN THE FORM OF CELLULOSE CAPSULES SUITABLE FOR BENZIMIDAZOLE DERIVATIVES | May 2009 | September 2011 | Abandon | 28 | 1 | 0 | No | No |
| 12464847 | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination | May 2009 | May 2011 | Abandon | 24 | 1 | 0 | No | No |
| 12445474 | HYDROPHOBIC ZINC OXIDE POWDER | April 2009 | January 2012 | Abandon | 33 | 1 | 0 | No | No |
| 12223503 | Methods and Compositions for Improving the Incorporation of Orthopaedic and Orthodontic Implants | March 2009 | June 2011 | Abandon | 35 | 1 | 0 | No | No |
| 11988805 | Implantable Medical Devices Comprising a Flavonoid or Derivative Thereof for Prevention of Restenosis | March 2009 | January 2012 | Abandon | 48 | 1 | 0 | No | No |
| 12393445 | HYDROXYCITRIC ACID SALT COMPOSITION AND METHOD OF USE FOR REDUCING BODY WEIGHT | February 2009 | January 2012 | Abandon | 35 | 1 | 0 | No | No |
| 12087455 | Method for Manufacturing a Pharmaceutical Form of Oseltamivir Phosphate | December 2008 | October 2011 | Abandon | 39 | 1 | 0 | No | No |
| 12094115 | PATHOGEN - CONTROLLING PRODUCTS | November 2008 | September 2011 | Abandon | 40 | 1 | 0 | No | No |
| 12259844 | VETERINARY FORMULATION FOR ADMINISTRATION OF A WATER-INSOLUBLE DRUG TO A TARGET ANIMAL THROUGH A WATER DISTRIBUTION SYSTEM | October 2008 | February 2015 | Allow | 60 | 2 | 1 | No | Yes |
| 12245223 | ADMIXTURE OF CAROTENOIDS HAVING PROVITAMIN A ACTIVITY AND CAROTENOIDS DEVOID OF PROVITAMIN A ACTIVITY FOR TREATING AGING SYMPTOMS | October 2008 | May 2011 | Abandon | 31 | 1 | 0 | No | No |
| 12225707 | Bulking of Soft Tissue using Drug Delivery Microspheres | September 2008 | October 2011 | Abandon | 36 | 1 | 0 | No | No |
| 12161355 | GEL-FORMING COMPOSITION FOR MEDICAL USE, ADMINISTRATION DEVICE FOR THE COMPOSITION, AND DRUG RELEASE CONTROLLING CARRIER | September 2008 | March 2012 | Abandon | 44 | 2 | 0 | No | No |
| 12207702 | ORALLY ADMINSTRABLE OPIOID FORMULATIONS HAVING EXTENDED DURATION OF EFFECT | September 2008 | May 2011 | Abandon | 32 | 1 | 0 | No | No |
| 12194996 | SYSTEM AND METHOD FOR MANUFACTURING ORAL OSMOTIC DRUG DELIVERY DEVICES, AND METHODS OF ADMINISTERING SAME | August 2008 | October 2011 | Abandon | 37 | 1 | 0 | No | No |
| 10586085 | Protease Inhibitors For the Treatment of Digestive Pathologies | August 2008 | September 2011 | Abandon | 60 | 1 | 0 | No | No |
| 12184492 | COLLOIDAL MAGNETIC NANOBIOPARTICLES FOR CYTOTOXICITY AND DRUG DELIVERY | August 2008 | September 2011 | Abandon | 38 | 1 | 2 | No | No |
| 12144285 | TRANSDERMAL DELIVERY SYSTEM COMPRISING GLYCOPYRROLATE TO TREAT SIALORRHEA | June 2008 | July 2011 | Abandon | 37 | 1 | 0 | No | No |
| 12083155 | Biocompatible Block Copolymer, Use Thereof and Manufacturing Method Thereof | June 2008 | July 2011 | Abandon | 39 | 1 | 0 | No | No |
| 12130657 | UROLOGICAL DEVICES INCORPORATING COLLAGEN INHIBITORS | May 2008 | November 2014 | Abandon | 60 | 4 | 1 | No | No |
| 12148302 | Topical antifungal treatment | April 2008 | July 2011 | Abandon | 39 | 1 | 0 | No | No |
| 12009220 | Pest control compositions and methods | January 2008 | July 2014 | Abandon | 60 | 3 | 1 | Yes | No |
| 11931897 | NON-SYSTEMIC CONTROL OF PARASITES | October 2007 | April 2015 | Abandon | 60 | 4 | 1 | Yes | Yes |
| 11766740 | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment | June 2007 | February 2013 | Abandon | 60 | 4 | 0 | Yes | Yes |
| 10532703 | Therapeutic compositions | January 2007 | May 2011 | Abandon | 60 | 0 | 1 | No | No |
| 11436391 | Methods and compositions relating to animal dietary acids | May 2006 | September 2011 | Abandon | 60 | 2 | 1 | Yes | No |
| 11434472 | Implantable devices for the delivery of therapeutic agents to an orthopaedic surgical site | May 2006 | August 2011 | Abandon | 60 | 1 | 2 | Yes | No |
| 11416488 | Non-sticky coatings with therapeutic agents for medical devices | May 2006 | October 2011 | Abandon | 60 | 4 | 0 | No | No |
| 11021309 | Enhanced absorption of modified release dosage forms | December 2004 | November 2010 | Abandon | 60 | 3 | 2 | No | No |
| 11022093 | Homeopathic sublingual dosage forms and methods thereof | December 2004 | June 2010 | Abandon | 60 | 2 | 1 | Yes | No |
| 10977805 | Single-dose taste inhibitor units | October 2004 | December 2010 | Abandon | 60 | 1 | 1 | No | No |
| 10932839 | Capsule containing active substance pellets | September 2004 | May 2011 | Abandon | 60 | 4 | 1 | Yes | Yes |
| 10875627 | Pulsatile release histamine H2 antagonist dosage form | June 2004 | June 2010 | Abandon | 60 | 2 | 1 | No | Yes |
| 10800031 | Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation | March 2004 | February 2015 | Abandon | 60 | 5 | 1 | No | Yes |
| 10736049 | TRANSDERMAL BUPRENORPHINE TO TREAT PAIN IN SICKLE CELL CRISIS | December 2003 | February 2008 | Allow | 50 | 2 | 0 | No | Yes |
| 10713929 | MODIFIED RELEASE DOSAGE FORMS OF SKELETAL MUSCLE RELAXANTS | November 2003 | March 2008 | Allow | 52 | 7 | 0 | Yes | Yes |
| 10693383 | Solid and semi-solid polymeric ionic conjugates | October 2003 | May 2009 | Abandon | 60 | 4 | 0 | No | No |
| 10213907 | Crystalline drug particles prepared using a controlled precipitation (recrystallization) process | August 2002 | March 2010 | Abandon | 60 | 10 | 0 | No | Yes |
| 10051708 | APPARATUS AND METHODS FOR PREVENTING OR TREATING FAILURE OF HEMODIALYSIS VASCULAR ACCESS AND OTHER VASCULAR GRAFTS | January 2002 | November 2003 | Allow | 22 | 1 | 0 | No | No |
| 09925348 | Solid pharmaceutical dosage formulation of hydrophobic drugs | August 2001 | December 2003 | Abandon | 28 | 3 | 0 | No | No |
| 09735125 | Method for disinfecting body fluids | February 2001 | January 2012 | Abandon | 60 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WAX, ROBERT A.
With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 9.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WAX, ROBERT A works in Art Unit 1615 and has examined 81 patent applications in our dataset. With an allowance rate of 9.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner WAX, ROBERT A's allowance rate of 9.9% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WAX, ROBERT A receive 1.95 office actions before reaching final disposition. This places the examiner in the 44% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by WAX, ROBERT A is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +13.9% benefit to allowance rate for applications examined by WAX, ROBERT A. This interview benefit is in the 51% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 6.2% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 22.2% of cases where such amendments are filed. This entry rate is in the 30% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 53% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 30.0% of appeals filed. This is in the 4% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 84.6% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.